William Blair Thinks Celyad’s Stock is Going to Recover


In a report released today, Raju Prasad from William Blair maintained a Buy rating on Celyad (CYAD). The company’s shares opened today at $24.75, close to its 52-week low of $22.17.

According to TipRanks.com, Prasad is a 2-star analyst with an average return of 0.6% and a 39.7% success rate. Prasad covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals Inc, Global Blood Therapeutics, and Logicbio Therapeutics Inc.

Celyad has an analyst consensus of Strong Buy, with a price target consensus of $48.50, representing a 96.0% upside. In a report issued on November 21, H.C. Wainwright also maintained a Buy rating on the stock with a $46 price target.

.

See today’s analyst top recommended stocks >>

The company has a one-year high of $48.20 and a one-year low of $22.17. Currently, Celyad has an average volume of 6,898.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Celyad SA is a clinical-stage biopharmaceutical company, which engages in the identification and development of specialized cell-based therapies. Its products include cardiopoiesis platform, immuno-oncology, and medical devices. The company was founded by Michel Lussier and William Wijns on July 24, 2007 and is headquartered in Mont-Saint-Guibert, Belgium.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts